Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CXCR2 | P25025 | 14/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.45 |
| ▸ | CCR6 | P51684 | 1/20 | 0.44 |
| ▸ | CXCR1 | P25024 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CFTR | P13569 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28089446 | 0.85 | MMP2 (0.56) | MMP2KMT2ASMN1; SMN2CXCR2CCR6 | |
| SCHEMBL8082335 | 0.82 | MEN1 (0.47) | MMP2MEN1KMT2ASMN1; SMN2CXCR2 | |
| SCHEMBL12261019 | 0.82 | MMP2 (0.53) | MMP2SMN1; SMN2GAAMAPTALDH1A1 | |
| SCHEMBL12260767 | 0.82 | MMP2 (0.53) | MMP2MEN1KMT2ASMN1; SMN2CXCR2 | |
| SCHEMBL16144436 | 0.82 | MMP2 (0.53) | MMP2KMT2ACXCR2KEAP1CXCR1 | |
| SCHEMBL12260953 | 0.82 | MMP2 (0.49) | MMP2KMT2ACXCR2CXCR1GAA | |
| SCHEMBL30598338 | 0.82 | SMN1; SMN2 (0.55) | MMP2MEN1KMT2ASMN1; SMN2KEAP1 | |
| SCHEMBL538290 | 0.82 | SMN1; SMN2 (0.55) | MMP2MEN1KMT2ASMN1; SMN2KEAP1 | |
| SCHEMBL720049 | 0.81 | MMP2 (0.72) | MMP2KMT2AGAAMAPTALDH1A1 | |
| SCHEMBL15069131 | 0.81 | MEN1 (0.46) | MEN1KMT2ASMN1; SMN2CXCR2KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8519168-B2 | Process and intermediates for the synthesis of 1,2-substituted 3,4-dioxo-1-cyclobutene compounds | MERCK SHARP & DOHME CORP. (US) | 2013-08-27 | — | — | US | claimed |
| US-20110160469-A1 | PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF 1,2-SUBSTITUTED 3,4-DIOXO-1-CYCLOBUTENE COMPOUNDS | MERCK SHARP & DOHME LLC | 2011-06-30 | — | — | US | claimed |
| EP-2178826-A1 | PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF 1,2-SUBSTITUTED 3,4-DIOXO-1-CYCLOBUTENE COMPOUNDS | SCHERING CORPORATION (US) | 2010-04-28 | — | — | EP | claimed |
| WO-2009005801-A1 | PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF 1,2-SUBSTITUTED 3,4-DIOXO-1-CYCLOBUTENE COMPOUNDS | SCHERING CORPORATION (US) | 2009-01-08 | — | — | WO | claimed |
| US-20240400501-A1 | 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF | ALLERGAN, INC. | 2024-12-05 | — | — | US | disclosed |
| US-20220402866-A1 | 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF | ALLERGAN, INC. | 2022-12-22 | — | — | US | disclosed |
| US-11208377-B2 | 3,4-disubstituted 3-cyclobutene-1,2-diones and use thereof | ALLERGAN, INC. (US) | 2021-12-28 | — | — | US | disclosed |
| US-11208377-B2 | 3,4-disubstituted 3-cyclobutene-1,2-diones and use thereof | ALLERGAN, INC. (US) | 2021-12-28 | — | — | US | disclosed |
| EP-3668832-A1 | 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF | Allergan, Inc. (US) | 2020-06-24 | — | — | EP | disclosed |
| WO-2019036374-A1 | 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF | ALLERGAN, INC. (US) | 2019-02-21 | — | — | WO | disclosed |
| WO-2019036374-A1 | 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF | ALLERGAN, INC. (US) | 2019-02-21 | — | — | WO | disclosed |
| US-20190047947-A1 | 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF | ALLERGAN, INC. | 2019-02-14 | — | — | US | disclosed |
| US-20070004682-A1 | Di-substituted oxadiazoles as CXC-chemokine receptor ligands | SCHERING CORPORATION | 2007-01-04 | — | — | US | disclosed |
| US-20060223864-A1 | Thiadiazoles AS CXC- and CC- chemokine receptor ligands | SCHERING CORPORATION AND PHARMACOPEIA DRUG DISCOVERY, INC. | 2006-10-05 | — | — | US | disclosed |
| EP-1694659-A1 | THIADIAZOLES AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS | SCHERING CORPORATION (US) | 2006-08-30 | — | — | EP | disclosed |
| WO-2005066147-A1 | THIADIAZOLES AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS | SCHERING CORPORATION (US) | 2005-07-21 | — | — | WO | disclosed |
| EP-1551818-A1 | THIADIAZOLEDIOXIDES AND THIADIAZOLEOXIDES AS CXC- AND CC-CHEMOKINE RECEPTOR LIGANDS | Pharmacopeia Drug Discovery, Inc. (US) | 2005-07-13 | — | — | EP | disclosed |
| US-20040186142-A1 | Thiadiazoledioxides and thiadiazoleoxides as CXC- and CC- chemokine receptor ligands | SCHERING CORPORATION PHARMACOPEIA, INC. | 2004-09-23 | — | — | US | disclosed |
| WO-2004033440-A1 | THIADIAZOLEDIOXIDES AND THIADIAZOLEOXIDES AS CXC- AND CC-CHEMOKINE RECEPTOR LIGANDS | SCHERING CORPORATION (US) | 2004-04-22 | — | — | WO | disclosed |
| US-4461827-A | Color photographic recording material containing a non-diffusible dye releaser from which a complexible azo dye is released during development | AGFA-GEVAERT AKTIENGESELLSCHAFT (DE) | 1984-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160469-A1 | PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF 1,2-SUBSTITUTED 3,4-DIOXO-1-CYCLOBUTENE COMPOUNDS | CCL2, CCR1, CXCR1 | MMP2 2261/4885MEN1 2745/4885KMT2A 4808/4885 |
| US-20060223864-A1 | Thiadiazoles AS CXC- and CC- chemokine receptor ligands | CCR2, ACKR3, CX3CR1 | MMP2 1170/4885MEN1 4674/4885KMT2A 4785/4885 |
| US-20040186142-A1 | Thiadiazoledioxides and thiadiazoleoxides as CXC- and CC- chemokine receptor ligands | CXCR1, CCR2, CX3CR1 | MMP2 1257/4885MEN1 4704/4885KMT2A 4824/4885 |
| US-20240400501-A1 | 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF | IL17A, TSLP, SSB | MMP2 4526/4885MEN1 674/4885KMT2A 4316/4885 |
| US-11208377-B2 | 3,4-disubstituted 3-cyclobutene-1,2-diones and use thereof | IL17A, TSLP, SSB | MMP2 4526/4885MEN1 674/4885KMT2A 4316/4885 |
| US-20220402866-A1 | 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF | IL17A, TSLP, SSB | MMP2 4526/4885MEN1 674/4885KMT2A 4316/4885 |
| US-20190047947-A1 | 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF | IL17A, TSLP, SSB | MMP2 4526/4885MEN1 674/4885KMT2A 4316/4885 |
| US-20070004682-A1 | Di-substituted oxadiazoles as CXC-chemokine receptor ligands | CXCR3, CXCR1, CXCR2 | MMP2 1346/4885MEN1 4818/4885KMT2A 4870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.